Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
Lists
Only you see this
Abstract
Cadonilimab plus neoadjuvant chemotherapy demonstrated favorable ORR and MPR with manageable toxicities in patients with head and neck squamous cell carcinoma.
BibTeX
@inproceedings{cao2025cadonilimab,
author = {Fei Cao and Yan Li and Qi Fang and Ruobin Lin and Zheng Zhao and Pengfei Xu and Honghong Yan and Xinrui Zhang and Ke Jiang and Jian Zhou and Chunyan Chen and Lixia Lu and Fei Han and Zhiming Li and Di Wu and Xuekui Liu},
title = {{Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial}},
booktitle = {Clinical},
year = {2025},
doi = {10.1158/1078-0432.ccr-25-1445},
}Loading related content...